MDA-MB-175-VII Xenograft Model Service for Breast Cancer

The MDA-MB-175-VII xenograft model delivers a validated in vivo translational platform designed to evaluate candidate therapies targeting unique, hormone-receptor-positive breast cancers driven by specific neuroregulin/HER signaling alterations. Alfa Cytology provides a comprehensive, end-to-end MDA-MB-175-VII xenograft model service, integrating fully authenticated cellular assets with standardized procedural and endocrine-supported protocols to accelerate preclinical oncology drug discovery timelines.

Overview of MDA-MB-175-VII Xenograft Model for Breast Cancer

The MDA-MB-175-VII cell line is a highly specialized and molecularly unique human mammary carcinoma model, clinically valued as a distinct tool for studying luminal subtype breast cancer. Originally isolated from the pleural effusion of a patient with advanced breast adenocarcinoma, this model characteristically expresses ERα. A defining biological hallmark of MDA-MB-175-VII is its autocrine signaling loop driven by the expression of heregulin (NRG1), which continuously stimulates the HER2/HER3 receptor heterodimers to promote cell survival and proliferation. This unique activation mechanism, occurring in the absence of classical HER2 gene amplification, makes the MDA-MB-175-VII model an indispensable preclinical test matrix for validating novel ER-alpha antagonists, SERDs, HER3-targeted antibodies, and next-generation ADCs.

When established in vivo as a xenograft in immunodeficient mice, MDA-MB-175-VII cells form solid tumors that faithfully preserve the unique histological architecture and biomarker signatures of human hormone-receptor-positive malignancies. Due to the characteristically slow growth kinetics profile inherent to this particular luminal line, robust tumor propagation in vivo requires highly precise cell calibration and mandatory supplementation with exogenous estradiol to maintain steady tumor development.

Fig 1. Seribantumab inhibits intracellular signaling in breast cancer cells with NRG1 fusion. (Odintsov I, et al., 2021)

Cell Line Information: MDA-MB-175-VII

The MDA-MB-175-VII cell line maintains a stable epithelial monolayer morphology in vitro and reliably preserves its primary ERα expression and autocrine heregulin signaling signatures upon in vivo transplantation.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the MDA-MB-175-VII Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, estradiol supplementation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC for ERα and HER3 pathway markers and PK/PD profiling. Leveraging our expertise in heregulin-driven luminal breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of MDA-MB-175-VII Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the MDA-MB-175-VII xenograft model:

• Cell Culture & Quality Control: MDA-MB-175-VII cells are cultivated in cell-bank-certified growth media under optimized parameters. Quality control verification involves mandatory STR profiling and mycoplasma clearance checks to guarantee phenotypic identity and purity before inoculation.
• Host Adaptation & Estrogen Priming: Standardized immunocompromised mice are selected based on study design and pre-implanted with controlled-release estradiol pellets. Animals are acclimated to controlled facility parameters to ensure baseline physiological and hormonal stability.
• Precision Inoculation: A calibrated suspension of high-viability MDA-MB-175-VII cells is prepared and blended with a verified biological matrix carrier to enhance cell survival. The mixture is precisely injected in vivo via subcutaneous or orthotopic routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers under continuous health monitoring. Animal weights and general behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 2. MDA-MB-175-VII Xenograft Model Construction Workflow

Case Study - MDA-MB-175-VII Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the MDA-MB-175-VII xenograft model was successfully utilized to evaluate the efficacy of a novel therapeutic candidate designed to block heregulin-mediated HER2/HER3 activation in hormone-receptor-positive breast cancer. Under optimized conditions featuring calibrated estradiol supplementation, our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms, allowing for an unobstructed and definitive assessment of therapeutic efficacy. The in vivo study successfully demonstrated significant, dose-dependent primary tumor growth inhibition in the treatment group compared to the vehicle control.

Our Advantages

Choosing the right partner for your heregulin-driven, hormone-dependent breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Model Authenticity: Fully verified human tumor cell lines with stable, traceable genetic hallmarks.
• Technical Consistency: Optimized inoculation and hormone-supplementation protocols ensuring uniform tumor growth and minimized variance.
• Multi-Parametric Endpoints: Capacity for advanced readouts, including digital tumor kinetics, target receptor expression analysis, and PK/PD tissue processing.
• Regulatory Compliance: Studies executed by a specialized team adhering strictly to international preclinical research standards.

Contact Us

Are you looking to advance your therapeutic pipeline against heregulin-driven, hormone-dependent breast cancer using the robust MDA-MB-175-VII xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.